1. Clinical features and laboratory findings of human parvovirus B19 in human immunodeficiency virus-infected patients.
- Author
-
Pereira RF, Garcia Rde C, Azevedo KM, Setúbal S, Siqueira MA, and Oliveira SA
- Subjects
- Adult, Anemia complications, Anemia diagnosis, Antibodies, Viral immunology, Antiretroviral Therapy, Highly Active, Biomarkers blood, CD4 Lymphocyte Count, Female, Genotype, HIV Infections drug therapy, Humans, Male, Medication Adherence, Middle Aged, Parvoviridae Infections complications, Parvovirus B19, Human genetics, Polymerase Chain Reaction, Antibodies, Viral blood, HIV Infections complications, Parvoviridae Infections immunology, Parvovirus B19, Human immunology, Parvovirus B19, Human isolation & purification
- Abstract
Immunocompromised patients may develop severe chronic anaemia when infected by human parvovirus B19 (B19V). However, this is not the case in human immunodeficiency virus (HIV)-infected patients with good adherence to highly active antiretroviral treatment (HAART). In this study, we investigated the clinical evolution of five HIV-infected patients receiving HAART who had B19V infections confirmed by serum polymerase chain reaction. Four of the patients were infected with genotype 1a strains and the remaining patient was infected with a genotype 3b strain. Anaemia was detected in three of the patients, but all patients recovered without requiring immunoglobulin and/or blood transfusions. In all cases, the attending physicians did not suspect the B19V infections. There was no apparent relationship between the infecting genotype and the clinical course. In the HAART era, B19V infections in HIV-positive patients may be limited, subtle or unapparent.
- Published
- 2014
- Full Text
- View/download PDF